The Filing Desk

Caribou Biosciences vs Janux Therapeutics

Caribou Biosciences CRBU · Janux Therapeutics JANX · Biotechnology

Caribou Biosciences reported revenue of $11 million in fiscal 2025, about the same as Janux Therapeutics' $10 million in fiscal 2025. Caribou Biosciences' revenue grew 11.7% in its latest year, and Janux Therapeutics' fell 5.5%. Caribou Biosciences had an operating margin of -1329.4%, against -1576.7% at Janux Therapeutics. Free cash flow was −$112 million at Caribou Biosciences and −$83 million at Janux Therapeutics.

Side by side

Caribou BiosciencesJanux Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$11M$10M
Revenue growth11.7%−5.5%
Revenue growth a year, last 5 years−2.0%—
Gross margin——
Operating margin−1,329.4%−1,576.7%
Net margin−1,327.4%−1,136.2%
Free cash flow−$112M−$83M
Free cash flow margin−1,006.8%−832.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.4%15.3%
Last close$0.31$10.29
P/E at the last close——
Insider trades, last 12 monthssold $33,875sold $457,063
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Caribou BiosciencesJanux Therapeutics
Operating margin
Percent of revenue
Caribou BiosciencesJanux Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Caribou BiosciencesJanux Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Caribou Biosciences and Janux Therapeutics pages.